Jacob Uno Stanley Gunterberg

Hjalmarsson & Partners Corporate Finance AB provides financial advisory services. It specializes in mergers, acquisitions, and equity capital raisings. The company was founded by UIf Hjalmarsson in 2000 and is headquartered in Stockholm, Sweden.

Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden.

Ancilla AB manages real properties. The company is headquartered in Stockholm, Sweden.

Healthcap Orx Holdings Gp AB is a private company that manages securities. The company is based in Stockholm, Sweden.

Part of Karo Healthcare AB, Trimb Holding AB operates as a holding Swedish company with interest in pharmaceuticals. The company is based in Stockholm, Sweden.

Cenova AB is a contract manufacturer with 50 years of experience in innovative and complex cleanroom manufacturing of plastic products. The private company is based in Mjölby, Sweden. The Swedish company's focus is on injection molding, vacuum forming, assembly, packaging, and sterilization. The company has the expertise and technology to manufacture products according to the market's toughest standards. The CEO of the company is Fredrik Holmgren.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

Lumavita AG is a specialty biopharmaceutical company dedicated to bring to market innovative anti-infectives for women's health. Based in Basel, Switzerland, Lumavita was recently financed by a syndicate, lead by Atlas Venture, with CHF18 million (EUR11 million). The company has one product under regulatory review in Switzerland and two further projects in clinical development.

HealthCap Advisor AB provides investment advice. The private company is based in Stockholm, Sweden.

Skipjack AB Manages real properties. The company is headquartered in Stockholm, Sweden.

INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Healthcap Annex Fund I-Ii Bis Gp AB operates as an investment holding Swedish company. The private company is based in Stockholm, Sweden.

Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland.

Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020.

Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg.